| NAC group(n = 45) | Placebo group(n = 45b) | P value |
---|---|---|---|
Primary end-point | Â | Â | Â |
   Incidence of CIN, n(%) | 5(11.1%) | 6(14.3%) | 0.656 |
Secondary end-points | Â | Â | Â |
   Change in serum creatinine, mg/dL | -0.016 ± 0.363 | -0.018 ± 0.467 | 0.975 |
   Change in serum urea nitrogen, mg/dL | -1.73 ± 24.03 | -3.71 ± 24.26 | 0.703 |
   Change in creatinine clearance, mL/min | 2.86 ± 8.84 | 3.78 ± 10.87 | 0.676 |